Skip to main
ABEO

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics Inc is projected to generate approximately $32 million in top-line revenue for 2025, with significant growth expected to reach $130.4 million in 2026, indicating strong revenue potential as the company advances its clinical programs. The favorable market access situation is anticipated to steadily improve, suggesting that the company's products may increasingly gain coverage and acceptance within the healthcare system. Additionally, the company's diverse pipeline assets in gene therapies and plasma-based products are expected to contribute positively to financial forecasts, driving potential upside in future performance.

Bears say

Abeona Therapeutics Inc. faces significant risks that contribute to a negative outlook on its stock, primarily centered around the commercial viability of its lead product, pz-cel. There are concerns regarding slower-than-expected adoption of pz-cel in the U.S. market, as well as challenges related to maximizing its value outside the United States. Additionally, potential setbacks in the company's earlier-stage pipeline programs and the risk of long-term dilution further exacerbate these challenges, limiting investor confidence in the company's future financial performance.

Abeona Therapeutics (ABEO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Abeona Therapeutics (ABEO) has a Strong Buy consensus rating as of Dec 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.